Comments by "Kristopher Driver" (@paxdriver) on "The Hill"
channel.
-
24
-
according to pharmacychecker Research July 2020: Marketing and sales costs vastly outpace spending on R&D so essentially the public is subsidizing marketing... which is kickbacks to doctors, insurers, media, etc. We're taxing the poorest people the highest portion of their income to charge them more for health issues which themselves also shrinks a person's ability to earn, save and invest more into escaping the cycle of poverty. We're double dipping on those least able to afford it in order to protect the arbitrage rights of the select few who are in the least need of financial aid. It's not complicated, we just need to stop paying for patents that corportations alone are profiting from. Just stop enabling corruption. It really is that simple.
2019 revenue in $mlns / R&D in $mlns / Marketing-Sales in $mlns
Eli Lilly $22,320 $5,595 $6,204
GlaxoSmithKline €21,891 €4,568 €11,402
Pfizer $51,750 $8,650 $14,350
Novartis $34,252 $9,402 $14,369
AbbVie $33,266 $6,942 $7,439
7